Figure 6.

Trametinib does not affect HUVECs proliferation and mobility. A-C. HUVECs were used to evaluate proliferation, migration, and invasion. HUVECs were stimulated by FBS or 50 ng/mL VEGFA and were treated with trametinib or vehicle. Cells proliferation is shown as mean percentage of cells viability compared with serum-Free untreated samples (SF) ± SD in quadruplicate. HUVECs migration is represented as mean number of migrated cells ± SD in triplicate. In both cases, representative results of three independent experiments are shown. D. Quantitative analysis of hemoglobin levels in HUVECs plugs. Data are from three independent experiments and are mean ± SD. n = 6, **P < 0.01 compared with wild type cells. E. VEGFA and CD31 levels from plugs tissues were analyzed through Western blot analysis.